Publication: Curr Opin Genet Dev. 2019 Mar 4;54:7-11. doi: 10.1016/j.gde.2019.02.003

Authors: Tiriac H, Plenker D, Baker LA, Tuveson DA.


Despite recent advances in the treatment of cancerpancreatic ductal adenocarcinoma (PDAC) still retains the worst survival rate of common malignancies. Late diagnosis and lack of curative therapeutic options are the most pressing clinical problems for this disease. Therefore, there is a need for patient models and biomarkers that can be applied in the clinic to identify the most effective therapy for a patient. Pancreatic ductal organoids are ex-vivo models of PDAC that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. Organoids models have been applied to pancreatic cancer research and offer a promising platform for precision medicine approaches.

Read full publication here:

Subscribe to our newsletter

Stay up-to-date on the latest advancements in 3D cell culture technology